Palonosetron

Palonosetron is a medication being studied in clinical trials for its effectiveness in preventing and treating nausea and vomiting, particularly in cancer patients undergoing chemotherapy. This article summarizes key findings from recent clinical trials evaluating different doses and administration methods of palonosetron for managing chemotherapy-induced nausea and vomiting (CINV) as well as postoperative nausea and vomiting (PONV).

Table of Contents

What is Palonosetron?

Palonosetron is a medication primarily used to prevent and treat nausea and vomiting. It belongs to a class of drugs called serotonin antagonists, specifically a second-generation 5-HT3 receptor antagonist[1]. Palonosetron is known by various brand names, including Aloxi®, Onicit, and Ruo Shan®[2][3].

Uses of Palonosetron

Palonosetron is primarily used for:

  • Chemotherapy-Induced Nausea and Vomiting (CINV): It helps prevent nausea and vomiting caused by cancer chemotherapy, especially moderate to highly emetogenic (likely to cause vomiting) chemotherapy[4].
  • Postoperative Nausea and Vomiting (PONV): It’s used to prevent nausea and vomiting after surgery[5].
  • Nausea and Vomiting in Terminally Ill Patients: Research is being conducted to evaluate its effectiveness in treating nausea and vomiting in terminally ill patients not related to chemotherapy[6].

How Palonosetron Works

Palonosetron works by blocking the action of serotonin, a natural substance in the body that can cause nausea and vomiting. Specifically, it inhibits the 5-HT3 receptors, which are involved in triggering the vomiting reflex. Palonosetron has a unique chemical structure and a longer half-life (the time it takes for half of the drug to be eliminated from the body) compared to older drugs in its class, which means it can provide longer-lasting protection against nausea and vomiting[1].

Administration and Dosage

Palonosetron can be administered in several ways:

  • Intravenous (IV) injection: Often given as a single dose of 0.25 mg before chemotherapy or surgery[7].
  • Oral capsules: Available in some countries for certain indications[3].
  • Subcutaneous injection: Being researched as an alternative to IV administration[8].

The dosage may vary depending on the specific condition being treated, the patient’s body weight, and other factors. Always follow your healthcare provider’s instructions regarding dosage and administration.

Effectiveness

Palonosetron has shown effectiveness in preventing nausea and vomiting in various clinical settings:

  • In chemotherapy patients, it has demonstrated superior efficacy compared to older anti-nausea medications[1].
  • For postoperative nausea and vomiting, studies have shown it to be effective in both adults and children[5].
  • Research is ongoing to determine its effectiveness in other situations, such as in terminally ill patients with nausea and vomiting not related to chemotherapy[6].

Side Effects and Safety

While palonosetron is generally well-tolerated, it can cause side effects in some patients. Common side effects may include:

  • Headache
  • Constipation
  • Dizziness
  • Fatigue

Serious side effects are rare but can include allergic reactions. If you experience any unusual symptoms after taking palonosetron, contact your healthcare provider immediately[3].

Special Populations

Research is ongoing to understand the effects of palonosetron in special populations:

  • Pediatric patients: Studies are evaluating its safety and efficacy in children[5].
  • Obese patients: Research is being conducted to determine optimal dosing for obese individuals[2].
  • Pregnant women: Limited data is available on its use during pregnancy, and it should be used only if clearly needed[3].

Ongoing Research

Several clinical trials are currently underway to further investigate palonosetron:

  • Comparing its effectiveness when combined with other anti-nausea medications[1].
  • Evaluating different dosing regimens and administration routes[8].
  • Assessing its efficacy in new patient populations or clinical scenarios[6].

These ongoing studies aim to optimize the use of palonosetron and potentially expand its applications in managing nausea and vomiting.

Aspect Details
Primary Use Prevention of chemotherapy-induced nausea and vomiting (CINV)
Secondary Uses Postoperative nausea and vomiting (PONV), nausea in terminally ill patients
Administration Methods Intravenous (IV), oral capsules
Typical IV Dose 0.25 mg
Mechanism of Action Serotonin (5-HT3) receptor antagonist
Effectiveness High efficacy in preventing acute and delayed CINV
Patient Populations Adults, being studied in pediatric patients
Common Side Effects Headache, constipation, dizziness
Unique Features Longer half-life compared to older 5-HT3 antagonists
Areas of Ongoing Research Optimal dosing, use in obese patients, combination with other antiemetics

Ongoing Clinical Trials on Palonosetron

  • A Study to Evaluate LY3537021 and a Drug Combination for Treating Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

    Recruiting

    2 1 1
    France Italy Romania Spain
  • Study of Adagrasib with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

    Recruiting

    3 1 1
    Austria Belgium Bulgaria Croatia France Germany +9
  • Study on the Effects of ZN-c3 for Patients with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    Recruiting

    2 1 1 1
    Belgium France Italy Poland Spain
  • Study on the Effectiveness and Safety of Selinexor for Patients with Myelofibrosis and Moderate Thrombocytopenia Who Have Not Used JAK Inhibitors

    Recruiting

    2 1 1 1
    Belgium Bulgaria Czechia Denmark France Germany +7
  • Study on Palonosetron and Netupitant for Preventing Nausea in Endometrial Cancer Patients Undergoing Taxane-Platinum Chemotherapy

    Recruiting

    3 1 1 1
    Italy
  • Study of palonosetron and fosaprepitant to prevent nausea and vomiting after laparoscopic surgery

    Not yet recruiting

    3 1 1
    Investigated diseases:
    Sweden
  • Study on the Effects of Plitidepsin for Adults with Long COVID Symptoms

    Not yet recruiting

    3 1 1
    Investigated diseases:
    Spain
  • Study of Plitidepsin Treatment for Adults with Post-COVID-19 Condition

    Not recruiting

    2 1 1
    Spain
  • Study of Azenosertib (ZN-c3) for Women with Recurrent or Persistent Uterine Serous Carcinoma

    Not recruiting

    2 1 1 1
    France Italy Spain
  • Study of Adagrasib with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

    Not recruiting

    2 1 1 1
    France Greece Hungary Italy Poland Spain

Glossary

  • Chemotherapy-induced nausea and vomiting (CINV): Nausea and vomiting that occurs as a side effect of cancer chemotherapy treatments.
  • Postoperative nausea and vomiting (PONV): Nausea and vomiting that occurs after surgical procedures, often as a side effect of anesthesia.
  • Serotonin antagonist: A type of medication that blocks the action of serotonin, a chemical in the body that can trigger nausea and vomiting.
  • Bioequivalence: The property of two drug products having the same biological effect in the body.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Complete response: In the context of anti-nausea treatment, this typically means no vomiting and no use of rescue medication.
  • Rescue medication: Additional medication given to treat symptoms when the primary treatment is not fully effective.
  • Emetogenic: Capable of causing nausea and vomiting. Chemotherapy drugs are often classified by their emetogenic potential.
  • Prophylaxis: Preventive treatment to stop a medical condition from occurring.
  • Half-life: The time it takes for half of a drug to be eliminated from the body.

References

  1. https://clinicaltrials.gov/study/NCT02205164
  2. https://clinicaltrials.gov/study/NCT02941913
  3. https://clinicaltrials.gov/study/NCT03148704
  4. https://clinicaltrials.gov/study/NCT01481831
  5. https://clinicaltrials.gov/study/NCT00828295
  6. https://clinicaltrials.gov/study/NCT00982995
  7. https://clinicaltrials.gov/study/NCT03586817
  8. https://clinicaltrials.gov/study/NCT01046240